Peak Bio
Peak Bio develops innovative therapies for inflammatory, rare, and specialty diseases, and cancer, with a focus on small molecules, antibodies, and ADCs. The company is listed on the OTCQB market under the symbol PKBO and has a research center in the Bay Area, California, and G&A infrastructure in South Florida.
Services
Peak Bio develops innovative therapies for inflammatory, rare, and specialty diseases, as well as cancer. The company's focus involves small molecules, antibodies, and antibody-drug conjugates (ADCs) to target specific conditions. Their pipeline includes treatments for Alpha-1 Antitrypsin Deficiency (AATD), acute respiratory distress syndrome (ARDS), and Trop2-expressing solid tumors.
Products
Peak Bio's prominent product is PHP-303, a fifth-generation, phase II-ready small molecule inhibitor of Neutrophil Elastase. PHP-303 is targeted at treating Alpha-1 Antitrypsin Deficiency (AATD) and acute respiratory distress syndrome (ARDS). Additionally, Peak Bio develops novel ADC product candidates using proprietary toxins like PH-1 to treat Trop2-expressing solid tumors.
Research and Development
Peak Bio maintains a center of research excellence in the Bay Area, California, and a G&A infrastructure in South Florida. The company is advancing innovative therapies through their platform of small molecules and ADCs. Their proprietary research includes PHP-303 and PH-1, showing promising results in inhibiting Neutrophil Elastase and targeting cancer cells, respectively.
Management Team
Peak Bio's management team brings over 50 years of industry experience in drug development, specializing in small molecules, antibodies, and antibody-drug conjugates. The team's extensive expertise supports the company's mission to develop groundbreaking therapies for life-threatening conditions.
Market Presence
Peak Bio is listed on the OTCQB market under the symbol PKBO. The company has received a non-dilutive pre-clinical grant from the Department of Defense (DoD) to explore PHP-303 for COVID-19-related ARDS, highlighting its active involvement in critical therapeutic research. The global Trop2 market, relevant to Peak Bio's ADC products, is expected to surpass $4 billion by 2026.